Evaluation of the effectiveness of a chemoprevention model of pancreatic adenocarcinoma using protein chip technology.
A serum-specific protein 'fingerprint' model was established which is capable of evaluating the effect of chemotherapy (gemcitabine) of pancreatic adenocarcinoma. We used SELDI-TOF-MS coupled with CM10 chips and bioinformatics tools to analyze a total of 45 mouse serum samples from three groups: the healthy control group, the pancreatic cancer model group (orthotopic transplantation model of human pancreatic adenocarcinoma) and the gemcitabine-treated group to establish diagnostic models. As a result, the test set yielded a specificity of 95.0% and a sensitivity of 95.0% for pattern 1, which distinguished pancreatic adenocarcinoma from healthy individuals and a specificity of 95.0% and a sensitivity of 75.0% for pattern 3, which distinguished healthy controls, PC model group and gemcitabine-treated group, as evaluated by leave-one-out cross-validation. We concluded from this study that the SELDI-TOF-MS technique combined with bioinformatics approaches can facilitate evaluating the effect of chemotherapy (gemcitabine) for pancreatic adenocarcinoma and could be used as a potential prognostic monitoring method.
Department of Surgery, Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310009, PR China. cao@zju.edu.cn
Liping
L
Cao
Liang
L
Wang
Guifeng
G
Wang
Daren
D
Liu
Jiekai
J
Yu
Risheng
R
Que
Dafei
D
Xie
D000230:Adenocarcinoma / Q000175:diagnosis* / Q000378:metabolism / Q000517:prevention & control*; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D054316:Biomarkers, Pharmacological / Q000032:analysis / Q000378:metabolism; D018890:Chemoprevention / Q000379:methods; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003940:Diagnostic Techniques, Endocrine; D006801:Humans; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D010190:Pancreatic Neoplasms / Q000175:diagnosis* / Q000378:metabolism / Q000517:prevention & control*; D040081:Protein Array Analysis; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / Q000379:methods; D016896:Treatment Outcome; D014407:Tumor Cells, Cultured; D023041:Xenograft Model Antitumor Assays; D000093542:Gemcitabine
D000970:Antineoplastic Agents; D054316:Biomarkers, Pharmacological; D003841:Deoxycytidine; D000093542:Gemcitabine